EGFR and non-small cell lung carcinoma: Among this population, approximately 13.5% (200,000–250,000 individuals) were expected to have advanced NSCLC with EGFR-wildtype PD-L1 TPS≥50% tumors that were unresectable or metastatic at diagnosis, and eligible to receive first-line PD1/PD-L1 monotherapy.